Dr. Apelbaum opened BI – Basel as Vice President, Brand Development in 2014 and was promoted to President, Basel in 2015. During his tenure with Brand Institute, Dr. Apelbaum has worked on 40+ INNs, 20+ medical device names and close to 200 pharmaceutical brand names. Prior to joining Brand Institute, he was with Actelion Pharmaceuticals as Regulatory Affairs
Consultant, in charge of the European regulatory strategy for two programs in clinical development for auto-immune diseases. Dr. Apelbaum was with Merck-Serono from 2010 to 2012 as Regulatory Compliance and International Liaison. From 2009 to 2010, he was International Regulatory Affairs Manager at Merck-Serono in charge of the regional registration and maintenance of the Merck Group’s range of biotechnology products for neurology (Rebif), endocrinology (Saizen), and fertility treatments (GONAL-f, Luveris, Cetrotide). From 2006 to 2008, he was Regulatory Affairs Consultant for Voisin Consulting, assisting biotech and pharma start-ups with their development in Europe. He earned his M.B.A. from HEC Lausanne and his Ph.D. in Neuroscience from Claude Bernard University.
